Source: CNBCTV18
Sun Pharmaceutical Industries Ltd. Indiaâs largest drugmaker, reported a mixed set of numbers for the quarter ended March 2025. While revenue and operating performance remained healthy, net profit declined sharply year-on-year, missing analyst expectations.
The company's revenue increase 8.1% to â¹`12,958.8Â compared to â¹11,982.9 crore in the previous year. A CNBC-TV18 poll had estimated a 9% increase in its revenue at â¹13,039.2 crore.
Net profit came in at â¹2,153.9 crore for Q4FY25, down 19% from â¹2,658.7 crore in the corresponding quarter last year. The Street had estimated a 10% increase in profit at â¹2,934 crore.
The pharma company's earnings before interest, taxes, depreciation and amortisation (EBITDA) was up 22.4% at â¹3,715.9 crore compared to â¹3,035.15 crore in the fourth quarter of the previous fiscal. The Street had pegged a 19% increase in its EBITDA at â¹3,618 crore.
The company's margin expanded to 28.7% from 25.3% in the year-ago period. A CNBC-TV18 poll had estimated the margin to be at 27.7% in the fourth quarter.
The companyâs board of directors has recommended a final dividend of â¹5.50 per equity share for the financial year 2024â25, subject to shareholder approval at the upcoming annual general meeting.
Ahead of the earnings announcement, shares of Sun Pharma closed 0.52% lower at â¹1,722.65 on the BSE.
Also Read: Here's why VRL Logistics shares surged 13% during Thursday's trading session
© Copyright 2025 . All Rights Reserved.
Privacy Policy